Clearside Biomedical Inc CLSD.OQ CLSD.O is expected to show a fall in quarterly revenue when it reports results on November 10 (estimated) for the period ending September 30 2025
The Alpharetta Georgia-based company is expected to report a 77.8% decrease in revenue to $230 thousand from $1.04 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Clearside Biomedical Inc is for a loss of 52 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Clearside Biomedical Inc is $75.00, about 94.6% above its last closing price of $4.02
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -1.31 | -1.51 | -0.90 | Beat | 40.6 |
Mar. 31 2025 | -1.59 | -1.63 | -1.65 | Missed | -1.3 |
Dec. 31 2024 | -0.60 | -1.46 | -1.50 | Missed | -2.9 |
Sep. 30 2024 | -1.78 | -1.86 | -1.50 | Beat | 19.5 |
Jun. 30 2024 | -1.93 | -2.02 | -1.50 | Beat | 25.9 |
Mar. 31 2024 | -2.08 | -2.06 | -2.25 | Missed | -9 |
Dec. 31 2023 | -1.23 | -1.31 | -1.20 | Beat | 8.6 |
Sep. 30 2023 | -2.33 | -2.32 | -2.25 | Beat | 3.2 |
This summary was machine generated November 7 at 11:57 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments